Ezetimibe
Green
Brand:
Nice TA:
385
Commissioning responsibility:
CCG
PbR excluded:
No
BNF chapter:
Cardiovascular system
Background
Ezetimibe monotherapy is recommended as an option for treating primary (heterozygous‑familial or non‑familial) hypercholesterolaemia in adults in whom statin therapy is contraindicated or not tolerated. Ezetimibe, co-administered with initial statin therapy, is recommended as an option for treating primary (heterozygous‑familial or non‑familial) hypercholesterolaemia in adults who have started statin therapy when:
-
serum total or low‑density lipoprotein cholesterol, is not appropriately controlled after dose titration of initial statin therapy or because dose titration is limited by intolerance OR
-
a change from initial statin therapy to an alternative statin is being considered.
Recommendation
LSCMMG Recommendation:
Green
Reason for decision:
Suitable for initiation in primary care
Supporting documents: